Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Patients with moderate COPD as defined by GOLD guidelines constitute almost 46% to 54% of all
diagnosed COPD patients. Yet limited data exists on characterizing this study population in
terms of drug therapy patterns and COPD-related resource use and costs. The objective of the
following study was to conduct an analysis in the real-world setting to (1) identify and
characterize COPD patients with moderate exacerbations and (2) evaluate the impact of
initiating different maintenance therapies in this population. Maintenance therapy
medications include inhaled corticosteroids (ICS), long-acting beta agonists (LABAs),
combination of ICS+LABA, and anticholinergics (ACs) including tiotropium (TIO) and
ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium
[IPR]).